Navigation Links
New Biologics Must Show Improvements in Efficacy, Safety and Cost-Benefit Compared with Currently Available Agents for Inclusion on Formularies in Argentina, Brazil and Mexico
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that novel biologics must demonstrate improvements in efficacy, safety and cost-benefit compared with currently listed agents for a given disease to be included on both national and institutional formularies in Argentina, Brazil and Mexico. According to the new Strategic Insights report entitled Trends in Reimbursement of Biologics Across the Growth Markets: Focus on Argentina, Brazil and Mexico, numerous novel biological agents are in late-stage development for a range of oncology indications, rheumatoid arthritis and diabetes, and could reach these markets in the next two to three years.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The report notes that the market for biologics is lucrative, and growth in this sector will outpace the overall oncology and rheumatoid arthritis drug markets, resulting in an increase share of biologics in these markets.

"While approval from the regulatory bodies of Argentina, Brazil and Mexico may be reached shortly after a drug's approval in the major pharmaceutical markets, it may precede inclusion on formularies in these markets by several years," said Decision Resources Group Analyst Natalia Reoutova, M.A., M.Sc. "Historically, authorization was sufficient for market access terms but today, it's only one step toward favorable market access."

About Strategic Insights
Strategic Insights is a new series of high-level, strategic rep
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
2. Synthetic Biologics Announces Proposed Public Offering of Common Stock
3. Synthetic Biologics SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
4. Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update
5. Synthetic Biologics to Report Third Quarter 2013 Financial Results
6. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
7. Samsung BioLogics unterzeichnet strategische Herstellungspartnerschaft mit Roche
8. Biosimilars Need Same Names as Original Biologics, Hospira Says at World Health Organization (WHO) Meeting
9. Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
10. Gallus Strengthens Biologics CMO Business with Acquisition of Laureate
11. Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... (PRWEB) October 17, 2014 ... offers a full line of Styrene-Butadiene polymer ... barrier coatings and a variety of other ... provide outstanding performance in these applications.  , ... in performance and cost effectiveness.  SB polymer ...
(Date:10/17/2014)... (PRWEB) October 17, 2014 The North ... concerned market in North America with analysis and forecast ... in 2013, and is expected to reach $1329.6 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. This also provides ...
(Date:10/17/2014)... Mediso stellt den MultiScan ... MultiScan-Produktreihe, das speziell für Forschungsanwendungen in der klinischen ... (Large Field of view Extreme Resolution) mit einem ... Sichtfeld in Breitenrichtung von 15 cm, einer PET-Auflösung ... % soll für die vorklinische Hirnforschung eingesetzt werden. ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 /PRNewswire/ ... - Research and Markets ( http://www.researchandmarkets.com/research/6cbkgn/latest_guidebook ) ... Guidebook for Conducting Medical Device Clinical Evaluation ... to Practices (2014 Edition)"  report to their ... , China,s regulatory framework ...
Breaking Biology Technology:Mallard Creek Polymers Reminds Industry of the Full Line of Styrene-Butadiene Polymer Emulsions 2The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 2The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 3Mediso enthüllt neues Forschungswerkzeug MultiScan LFER 150 PET/CT 2Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) 2Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) 3
... Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), ... tumor specific data to enhance the value of oncology drugs, today ... 2009. Full details of the Company,s financial results are available in ... , Total revenues for the first quarter of ...
... SINGAPORE, Sept. 14 China Agro-Technology Holdings (OTC ... website which is focused on spotlighting the company,s focus on ... website is located at www.chinaagrotech.com. , , ... Holdings Ltd., headquartered in Singapore, is focused on becoming a ...
... , , ... 14 Tobira Therapeutics Inc., a clinical stage biotechnology ... treatment of life-threatening and life-altering infectious diseases, today announced ... randomized study of TBR-652 in sixty healthy volunteers. ...
Cached Biology Technology:Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 5Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2
... calls for policymakers to reduce both nitrogen and phosphorus ... problems in fresh and coastal waters. In the ... argue that dual-nutrient reduction strategies are likely to be ... phosphorus in fresh and coastal water ecosystems. "If ...
... 2009 ― Protecting drinking water and preventing harmful ... many lakes, will require reducing both nitrogen and ... to the sea, management strategies should be implemented ... that focus only on one nutrient will fail. ...
... be exhausting. When fruit flies mate, the females, genes ... an immune reaction starts. This is shown in a ... the scientific publication, Journal of Evolutionary Biology .* ... genomic technology, so-called microarrays, researchers at Uppsala University can ...
Cached Biology News:Nutrient pollution chokes marine and freshwater ecosystems 2
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
Biology Products: